Form 8-K - Current report:
SEC Accession No. 0001193125-23-248188
Filing Date
2023-10-02
Accepted
2023-10-02 07:42:29
Documents
12
Period of Report
2023-09-12
Items
Item 1.03: Bankruptcy or Receivership
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d516484d8k.htm   iXBRL 8-K 24173
  Complete submission text file 0001193125-23-248188.txt   149359

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA atnx-20230912.xsd EX-101.SCH 2850
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE atnx-20230912_lab.xml EX-101.LAB 18705
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atnx-20230912_pre.xml EX-101.PRE 11695
6 EXTRACTED XBRL INSTANCE DOCUMENT d516484d8k_htm.xml XML 3766
Mailing Address 1001 MAIN STREET SUITE 600 BUFFALO NY 14203
Business Address 1001 MAIN STREET SUITE 600 BUFFALO NY 14203 716-898-8625
Athenex, Inc. (Filer) CIK: 0001300699 (see all company filings)

EIN.: 431985966 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38112 | Film No.: 231297762
SIC: 2834 Pharmaceutical Preparations